There is now substantial evidence supporting a role of the natriuretic peptides as a major defence mechanism against excess salt and water retention and high blood pressure. Because of this there has been considerable interest in the therapeutic potential of the natriuretic peptide system. Several approaches have been explored including the use of native peptides, the development of natriuretic peptides mimetics and targetting of endogenous clearance of natriuretic peptides. While ANP and BNP administration may be valuable in some circumstances, however, the limitations of the use of peptides especially for long-term treatment are well apparent. In view of this, considerable effort has been devoted to the development of orally active agents to enhance endogenous natriuretic peptides through inhibition of breakdown by neutral endopeptidase. This research has now led to the vasopeptidase inhibitors -dual inhibitors of both endopeptidase and angiotensin converting enzyme. These agents clearly provide a novel approach to enhance endogenous natriuretic peptide function on a background of reduced angiotensin II activity and may lead to an important advance in the treatment of hypertension and of conditions associated with overt salt and water overload.
Introduction
(CNP) [8] . These peptides are synthesised as high molecular weight precursors that undergo processing to the mature The major cardiovascular and renal actions of atrial forms which are located within the C-terminal region of natriuretic peptide (ANP) and the fact that the atria are the corresponding precursors. Despite some differences in strategically located to sense changes in intravascular sequence, a key feature of these peptides is the presence of volume cleary point to ANP as an important factor in the a highly conserved 17-amino acid long S-S ring core overall control of sodium balance and blood pressure ( Fig. 1 ). [1] [2] [3] . The importance of ANP in the control of sodium BNP, originally isolated from porcine brain, and subexcretion is strengthened by more recent experiments in sequently, also isolated from the human heart, has a similar transgenic mice in that mice with ANP gene deletion and pattern of renal and cardiovascular actions to ANP [9] . those with natriuretic peptide type A receptor knock-out Even though there are differences in pro-hormone processdisplayed higher blood pressures and substantial impairing, storage and release between ANP and BNP [8] , ment in the renal response to volume overload [4] [5] [6] . The circulating and cardiac levels of BNP are also raised in markedly raised plasma levels of ANP in humans with patients with cardiovascular and / or renal disease [7] . conditions associated with impaired renal sodium excretion CNP displays some sequence homology with ANP, but and overt volume expansion also points to the potential lacks the C-terminal extension segment. Despite its name, importance of ANP as a compensatory mechanism in the the major systemic effects of CNP are vasodilatory rather presence of volume overload [7] . than natriuretic. However, CNP is also made within the However, it is now apparent that ANP is part of a larger brain and there is evidence that it may contribute to the family of homologous natriuretic peptides including brain control of salt and water balance through central mechanatriuretic peptide (BNP) and C-type natriuretic peptide nisms [10] . Within the circulation, CNP is also produced terminal extension, it has strong homology with the human ANP especially within the disulphide ring. DNP has similar renal and cardiovascular actions to ANP [17] . DNP-like immunoreactive material has now been identified in dog [17] and human heart [18] but the function of DNP-like peptide in mammals is unclear -it may act as further back-up mechanism for ANP and BNP but this remains to be established. In view of the potent vasodilatory and natriuretic properties of ANP (Table 1 ) and of the realisation of the potential pathophysiological significance of ANP and BNP in hypertension and in conditions associated with abnormalities in sodium balance there has been considerable interest in the development of ANP mimetics and of orally active inhibitors of the endogenous clearance of natriuretic natriuretic peptide system in cardiovascular disease with particular emphasis in the treatment of hypertension and of by endothelial cells [10] and therefore may have a local conditions associated with overt expansion of the extracelrole in the regulation of vascular tone. In fact, recent work lular fluid volume such as congestive heart failure and suggests that CNP may be co-released with nitric oxide renal failure. More specifically the review will focus on the and may be important in modulating both vascular tone potential therapeutic value of ANP and BNP, on the neutral and the development of atheromatous vascular disease endopeptidase (NEP) inhibitors and on the newly intro- [11, 12] .
duced vasopeptidase inhibitors -dual inhibitors of ACE In addition to these, a 32-amino acid extended form of and NEP. ANP characterised by the presence of an additional fouramino acid sequence at the N-terminal site of ANP has also been isolated [13] . This peptide, termed urodilatin, 2. Receptor mechanisms and metabolism of differs from ANP in that it appears to be made mainly natriuretic peptides within the kidney [14] . Peptide infusion in humans has similar natriuretic effects as with infusion of ANP [15] ;
Soon after the identification of ANP as a novel peptide it however, urodilatin has not been found in blood and does was found that the peptide stimulated the production of not appear to be part of the circulating natriuretic peptide cyclic GMP in several target tissues (e.g., renal, vascular system. and adrenal). Subsequently it was discovered that ANP More recently, several natriuretic peptides have been was a potent activator of the particulate guanylate cyclase, identified in other animals; remarkably, one of these thereby highlighting cyclic GMP as the second messenger (DNP) isolated from the venom of the green mamba [16] for the actions of ANP. That this was the case was is 38 amino acids long, and despite a much longer Cconfirmed by using molecular cloning methods to derive [19] .
domain, but by contrast it lacks the intracellular catalytic However, it is now apparent that there are at least three domains of guanylate cyclase. All three natriuretic peptides major types of receptors ( Fig. 2) with different affinities bind to this receptor with similar affinity. NPR-C is widely for the different forms of naturally occurring natriuretic expressed in a variety of tissues, however, the pattern of peptides [20, 21] . The full sequence of these receptors has NPR-C expression is not identical to that of NPR-A. While been identified from molecular cloning methods and both receptors have been identified in the kidney, adrenal, sequence analysis of the different receptors has provided lung, and heart, colocalisation of both is only prominent in an insight into the structural features important for funcrenal glomeruli. Some studies have suggested that the tional activity.
NPR-C may have a role in signal transduction as ANP led The three natriuretic peptide receptors identified in to inhibition of cyclic AMP production in isolated rat mammalian tissues have been designated as NPR-A, NPRplatelets [23] . Other investigations have demonstrated that B and NPR-C. Natriuretic peptide receptors A and B are atrial peptides have stimulatory effects on phosphoinositide linked to the production of cyclic GMP and mediate many hydrolysis in cultured bovine aortic smooth muscle cells. of the cardiovascular and renal effects of the natriuretic Both of these effects appear to be mediated through a peptides. The A receptor binds both ANP and BNP, guanine nucleotide regulatory protein [24] . although it is more selective for ANP. By contrast CNP While research continues on the possible links between appears to be the natural ligand for the B receptor. These the NPR-C receptor and G-proteins linked cyclic AMP two receptors are structurally similar, with approximately production and on the cellular mechanisms for the antig-44% homology in the ligand-binding extracellular domain.
rowth properties of natriuretic peptides, it is now generally In both receptors, the predicted catalytic domain of the accepted that the NPR-C receptor seems to be of major guanylate cyclase is located within the intracellular region, importance in the metabolic clearance of natriuretic pepthis region of the receptor also contains a putative kinasetides. This is supported by several observations. Firstly, like domain upstream of the guanylate cyclase domain there is evidence of an enhanced renal response as a result [22] . The protein kinase-like domain seems to function as a of NPR-C blockade as suggested by original experiments regulatory element. When the kinase-like domain was of Maack et al.
[25] who first described a role for NPR-C removed by deletion mutagenesis, the resulting ANP in hormonal clearance and buffering. These infused an receptor retained guanylate cyclase activity, but this activi-ANP analog that was selective for the NPR-C receptor in ty was independent of ANP and its stimulation by ATP the isolated, perfused rat kidney with the native rat ANP was markedly reduced [22] . and found a trend toward both increased potency and an The third receptor NPR-C, is also a membrane bound increased maximal response for urinary sodium excretion. Secondly, more recent experiments in isolated cells have demonstrated that ANP bound to NPR-C is rapidly internalised and subsequently degraded in a lysosomal compartment prior to receptor recycling to the cell surface [26] . Since under normal conditions there is a large reserve capacity (99%) of unoccupied NPR-C, this receptor provides an efficient mechanism for the clearance of circulating natriuretic peptides and for local modulation of the physiological effects of natriuretic peptides [27] . Both ANP and BNP are rapidly removed from the circulation. In humans, infusion studies with ANP have demonstrated a biexponential decay curve with a fast (half-life, 1-4 min) and a slower elimination behaviour (half-life, 5-15 min) [28] . In humans however, there are differences between BNP and ANP as the half life of the infused hBNP-32 is about 7-fold that of ANP [29] . This lower clearance may due to the lower affinity of BNP for the NPR-C and also for the guanylate cyclase linked NPR-A. Several tissues are involved in the elimination of endogenous natriuretic peptides. The lungs, liver, and kidneys are important in the elimination of natriuretic peptides. In addition to the clearance through binding to the specific NPR-C receptor another major disposal mechanism is enzymatic inactivation by neutral endopeptidase (EC 24.11) [30] . Neutral endopeptidase (NEP) is a metal-lopeptidase widely distributed and also present within renal acids. The results demonstrated that successive elimination tubular cells and vascular cells. NEP cleaves the Cys-Phe of these amino acids led to substantial and progressive bond in ANP thereby leading to a relatively inactive reductions in receptor binding affinity and loss in potency peptide. By contrast, BNP is cleaved at different sites of biological activity. These observations clearly suggest within the peptide but, in sheep at least, NEP inhibition that the binding of ANP to its biologically active receptor increased both ANP and BNP to a similar extent [31] . The is highly sensitive to the conformation of ANP and making relative proportion of each of these two clearance pathit difficult to devise reduced size analogues. However, Li ways to the elimination of natriuretic peptides in humans is et al. [35] using a novel approach described a reduced size not known. However, from investigations in animals, each ANP analog of 15 amino acids which displayed a relasystem probably accounts for approximately half of the tively high potency for the type A receptor. This was turnover of ANP and BNP [32] .
achieved by the identification of a functional epitope for receptor binding which was placed onto a smaller ring 7 2 3 (Cys -Cys ). Biological activity was then restored by 3. Reduced size ANP analogs and designer natriuretic optimising the remaining non-critical residues by means of peptides phage display. Despite the substantial reduction in size, the 15-residue ANP analogue (mini-ANP) displayed a high Natriuretic peptides are relatively large peptides and binding affinity for the ANP-A receptor (EC , 0.48 nM) 50 given the limitations in the use of peptides, from a and biological activity (EC , 5.9 nM) and on a compara-50 therapeutic point of view there is clearly scope to develop tive basis, the mini ANP was about 7 times less potent than lower molecular weight analogs -even better, there is the native ANP. scope to develop orally acting agents with ANP mimetic activity or substances which selectively enhance endogen-3.2. Vasonatrin ous levels and activity of natriuretic peptides Accordingly there has been an intense effort on underThe differences in profile of action of ANP and CNP standing structure-function relationships of natriuretic pephave been exploited in an apparently novel way in the tides, and of ANP in particular, in an attempt to reduce the synthesis of vasonatrin. Wei et al. [36] worked on the size of the peptide and yet maintain its full biological hypothesis that addition of the C-terminal segment from activity [33] . Biological activity of ANP is not markedly ANP to CNP would lead to a unique peptide with dependent on the presence or actual type of amino acid combined venodilation and natriuresis. This chimeric around the N-terminal segment. Rat ANP tolerates removal peptide was tested both in vitro and in vivo and as of up to four amino acids before the disulphide bridge expected proved to have natriuretic and venorelaxant without much change in natriuretic or vasorelaxant activiactivity that was intermediate in potency to that observed ty. By contrast, biological activity is markedly dependent with ANP or CNP alone. Interestingly, vasonatrin dison the length and type of amino acid of the C-terminal played more potent arterial venodilation than either of the segment. Sequential deletion of each of the amino acids in original peptides. this region leads to gradual and substantial reduction in
The potent venodilating and natriuretic actions of vasnatriuretic effects, vasorelaxant activity and receptor bindonatrin mimic the actions of both diuretics and nitrates ing affinity. Moreover, activity is also markedly dependent suggesting a unique therapeutic potential for hypertension on the specific amino acid in this region suggesting that and for congestive heart failure. However, its action may this region is important for receptor binding and stimulabe limited by its unusually marked arterial vasorelaxing tion.
actions. The mechanisms for the greater vasorelaxation of The disulphide bridge is required for expression of full veins and arteries of vasonatrin compared with the parent activity, as it stabilises the biologically active conformapeptides are as yet unclear but may be related to differtion of the peptide, but is not an absolute requirement for ences in degradation. Another possibility is that the biological activity since linear peptides still retain residual chimeric peptide may interact with the clearance receptor activity. Further investigations have identified structural and so displaces both endogenous ANP and CNP or characteristics within the ring that discriminate between stimulate an as yet unknown receptor that is not activated the NPR-A and the NPR-C type receptors and has led to by ANP or CNP. Despite these unresolved issues, this the development of reduced size ANP analogues (mini work clearly forms a basis for the development of new ANP), and 'designer' natriuretic peptides (vasonatrin and peptides with specific actions on specific target organs and NPR-A specific ANP analogues).
tissues.
3.1. Mini ANP 3.3. NPR-A specific natriuretic peptides Schiller et al. [34] prepared ANP analogs with deletion of the residues in the C-terminal region of the ring More recent investigations on the structure-function structure through successive elimination of selected amino relationship of natriuretic peptides has focused on the identification of natriuretic peptide analogs more selective general, significant natriuretic effects with variable and for the A-type receptor compared with the C-type receptor.
small reductions in blood pressure were observed. Other The rationale for this is that these analogs would be studies addressed the effects of low-dose and short-term expected to have decreased metabolic clearance, a longer infusion (up to 3 h) to achieve plasma levels of only half-life and increased potency. Moreover, there is also the around 2-fold over basal levels. There were significant potential for enhanced responsiveness in the kidney, natriuretic and diuretic effects and haemoconcentration because coexpression of NPR-C and NPR-A in the kidney suggesting reductions in intravascular volume in some may attenuate the response to peptide binding to both cases. The effects on plasma renin and aldosterone were receptors.
small (or not significant) [40, 42, 43] . Despite these effects, One group [37] used the novel approach of mutant ANP however, there were no consistent reductions in blood phage display libraries to develop human ANP analogs pressure. Further work [41] , however, demonstrated that which displayed much higher affinity for the NPR-A effective hypotensive actions of low-dose administration of compared with the NPR-C receptor. However, further ANP is likely to require more prolonged and sustained investigation of the in vivo effect of this peptide were infusion of ANP (more than 12 h), thereby limiting its hampered by the species specificity as the human recombipotential value when compared with existing antihypernant peptide had a much reduced affinity for rat NPR-A.
tensive agents. To overcome this problem these authors subsequently used a similar approach to develop an ANP analog with a high 4.2. ANP for renal failure affinity for the rat NPR-A receptor compared with rat NPR-C receptor. This analog retained full potency com-
The renal effects of ANP, and in particular, increased pared with the parent rat ANP in both the cyclic GMP glomerular filtration rate, inhibition of renal tubular restimulation assays and in the relaxation of pre-constricted absorption of sodium and chloride, and redistribution of aortic rings [38] . Consistent with the earlier functional blood flow to the renal outer medullary region pointed to work, structural features determining receptor selectivity beneficial value in the treatment of acute renal failure in were located within the disulphide bridge. More interestcritically ill subjects. This led to investigate the effects of ingly, however, the new peptide when infused in the intact ANP in patients with renal failure using anaritide a 25-rat displayed more marked depressor and natriuretic effects amino acid synthetic form of ANP. Allgren et al. [44] compared with the native rat ANP.
reported a multicenter, randomised, double-blind, placeboThe differences in these effects did not appear to be due controlled clinical trial of anaritide infusion (0.2 mg / kg per to differences in neutral endopeptidase-mediated breakmin) over a 24-h period in critically ill patients with acute down and hence were probably due to differences in tubular necrosis. The primary end point was dialysis-free selectivity for the NPR-A and the NPR-C receptors. These survival for 21 days after treatment. Other end points results therefore provide further evidence for a specific role included the need for dialysis, changes in the serum for NPR-C in the clearance of endogenous ANP and creatinine concentration, and mortality. The results showed thereby in the local attenuation of the effect of ANP. The that the administration of anaritide did not improve the importance of these investigations into the structure-funcoverall rate of dialysis-free survival in critically ill patients tion relationship of natriuretic peptides is underscored by with acute tubular necrosis. A separate investigation [45] the prospect that natriuretic peptide analogues more selecexamined safety and efficacy of this peptide compared tive for the NPR-A receptor may well have improved with placebo in patients with oliguric acute renal failure in activity over native ANP for the treatment of acute renal a multicenter, randomised, double-blind, placebo-confailure and acute heart failure.
trolled trial. Although a trend was present, there was no statistically significant beneficial effect of ANP in dialysisfree survival or reduction in dialysis. Another study in 4. ANP and BNP as therapeutic agents people with chronic renal failure evaluated the efficacy of anaritide in patients with radiocontrast-induced nephroWhile work is continuing to develop the 'designer pathy (RCIN) a common cause of hospital-acquired acute peptides' along the lines described above for use in renal failure associated with a high mortality rate. The humans, numerous studies have investigate the potential results showed that the infusion of anaritide before and therapeutic value of infusion of native ANP and BNP in during a radiocontrast study did not reduce the incidence several conditions and in particular in patients with of RCIN in patients with preexisting chronic renal failure. essential hypertension, renal failure or congestive heart This is consistent with the other two studies in patients failure.
with chronic renal failure and questions the value of ANP infusion in these situations. 4.1. ANP for essential hypertension 4.3. ANP and BNP for congestive heart failure Several early studies investigated the effects of exogenous ANP infusion in essential hypertension [39] [40] [41] [42] [43] . In Several groups investigated the effects of ANP in patients with congestive heart failure (CHF) [47] [48] [49] [50] [51] [52] [53] . The ly (as compared with an increase of 2.0 mmHg with initial studies examined the effects of high doses ANP, placebo, P,0.001). This was associated with an improvegiven either as bolus or as infusion (.5 mg / min). These ment in global clinical status. In the comparative trial, the observed an attenuation of natriuretic and diuretic reimprovements in global clinical status, dyspnoea and sponses in patients with CHF compared with healthy fatigue were sustained with nesiritide therapy for up to 7 volunteers. This blunted effect could be due to concurrent days. The improvements were similar to those observed activation of counter-regulatory systems or to the haemowith standard intravenous therapy for severe congestive dynamic effect of reductions in blood pressure on renal heart failure consisting primarily of dobutamine or milfunction. Nonetheless, and despite these blunted responses rinone. The authors concluded that the salutary clinical and it was also apparent that ANP infusion in patients with haemodynamic profile of nesiritide would be a valuable CHF decreased intracardiac pressures and increased caraddition to the initial treatment of patients admitted to the diac output, thereby suggesting potential beneficial effects.
hospital for decompensated congestive heart failure. Similarly, Goy et al. [50] using an infusion rate of 0.5-2
Despite these encouraging results, however, there is mg / min also confirmed beneficial effects in patients with some concern on the side effects of nesiritide [59] . The CHF. At these doses there were no effects on blood most common of these was dose-related hypotension. Also, pressure, heart rate or systemic vascular resistance conother studies found that nesiritide was associated with sistent with a reduction in preload. However, increased sodium and water retention and decreased urine output in sodium and water excretion were not maintained over a some patients with CHF. Although this may have been due prolonged 20 h infusion of ANP.
to an imbalance in diuretic use, nesiritide-treated patients By contrast, other investigations have demonstrated also experienced three cases of renal failure [59] . These more sustained beneficial haemodynamic effects during issues clearly need to be addressed and additional studies infusion of human BNP in subjects with CHF [54] [55] [56] .
need to be undertaken to further evaluate the benefits of These effects included reductions in cardiac filling BNP in patients with congestive heart failure. pressures, and increased cardiac index. During infusion of BNP, there were also significant increases in urinary sodium excretion but, the absolute increase and the fractional excretion of sodium in response to BNP was lower 5. Pharmacological manipulation of endogenous in the CHF patients compared with normal controls [56] .
natriuretic peptides Further studies on the value of BNP in CHF has now been carried out with nesiritide, a purified human BNP produced Although the use of natriuretic peptides given as ANP or by recombinant DNA technology [57, 58] . These studies BNP may be of value in some circumstances as for have shown beneficial haemodynamic, neurohormonal and example in severe congestive heart failure on a short-term renal effects after bolus administration and 6-h infusion of basis, it is nevertheless also evident that the use of peptides nesiritide in CHF patients. Nesiritide was associated with has limited application. Hence, because of the problems significant decreases in pulmonary capillary wedge associated with application of peptides (e.g., parenteral pressures and systemic vascular resistance with increases administration, rapid elimination, high commercial costs, in cardiac index. This occurred in the absence of increases etc.), especially in conditions likely to need long-term in heart rate. Treated patients also experienced improved treatment considerable efforts have been made in the symptoms of dyspnoea and fatigue. development of orally active inhibitors to block breakdown Although it has generally been assumed that improved by neutral endopeptidase (NEP). haemodynamic function will result in the resolution of NEP is widely distributed; the kidney is a rich source of symptoms in patients with decompensated congestive heart the enzyme but the enzyme is also found within the CNS failure, most studies of new drugs for this purpose have where it appears to be involved in the inactivation of focused on haemodynamic, rather than symptomatic end neuropeptides [60] . This enzyme also breaks down enpoints. To determine the clinical value of nesiritide, a kephalins and inhibitors of this enzyme were originally study group [58] undertook an efficacy and a comparative developed more than two decades ago as 'enkephalinase' trial involving a total of 432 patients who were hospitalinhibitors [61] . Once it was apparent that neutral endoised because of decompensated congestive heart failure. In peptidase also hydrolysed natriuretic peptides, these 'enthe efficacy trial, a double-blind, placebo-controlled design kephalinase' inhibitors were also examined in terms of was used to determine the short-term efficacy of nesiritide their renal and cardiovascular effects in experimental with regard to haemodynamic measures and symptoms. models of hypertension or heart failure. The comparative trial compared nesiritide with standard When tested in animals endopeptidase inhibitors were intravenous agents,which served as active controls, in associated with increases in ANP and displayed marked terms of clinical efficacy and adverse events.
natriuretic effects suggesting a potentiation of the renal In the efficacy trial, nesiritide (infusion at rates of 0.015 effects of natriuretic peptides. The effects on blood presand 0.030 mg / kg per min for 6 h) decreased pulmonarysure in the SHR was more variable in that some but not capillary wedge pressure by 6.0 and 9.6 mmHg, respectiveevery study demonstrated reductions in blood pressure, but some studied demonstrated significant blood pressure were randomised into five equal groups to receive placebo reductions in the DOCA-salt hypertensive rat, a model of or one of four doses (50, 100, 200, or 400 mg twice daily) volume expanded hypertension [62] [63] [64] [65] [66] .
of the NEP inhibitor ecadotril over a 13-week period. All Subsequent work in normal humans confirmed the patients enrolled were receiving inhibitors of angiotensineffects found in animal experiments as several studies converting enzyme and conventional diuretic therapy. This using mainly the NEP inhibitor candoxatril showed an study however did not suggest that ecadotril could be increase in plasma ANP, an increase in renal sodium and promoted for the treatment of congestive heart failure. water excretion and an associated increases in both plasma Firstly, patient-reported symptoms and quality-of-life and urinary cyclic GMP [67] [68] [69] [70] [71] [72] . These observations scores failed to reveal any important, overall symptomatic clearly reproduce those observed after infusion of low benefit. Secondly, there was adverse event profile and in doses of exogenous ANP, thereby suggesting that the particular at the highest dose of ecadotril, there was a actions of these inhibitors may be mediated through relatively high frequency of aplastic anaemia. This led to increased levels of ANP and possibly also of BNP. Related cessation of clinical development of higher doses and to work explored the potential therapeutic value of NEP reassessment of the possible risk / benefit ratio for lower inhibitors in several conditions and in hypertension and doses of ecadotril. congestive heart failure in particular.
However, and despite the apparent enhancement of ANP activity, the majority of studies found no substantial reductions in blood pressure both in normotensives and in 6. Vasopeptidase inhibitors people with hypertension [67] [68] [69] [70] [71] [72] [73] . Similar observations were also made when the NEP inhibitor candoxatril was While NEP inhibitors increase activity of endogenous given on a longer-term basis term (200 mg twice daily for natriuretic peptides, the concomitant enhancement of the 28 days) in individuals with essential hypertension [74] .
effects of vasopressor peptides, angiotensin II in particular, One possible reason for the limited effectiveness of NEP is likely to offset their antihypertensive effects. Because of inhibitors as antihypertensive agents seems to be related to this, there has been considerable interest in combining the non-specificity of this enzyme. NEP hydrolyses not NEP inhibitors with angiotensin converting enzyme inonly vasodepressor peptides (e.g., natriuretic peptides and hibitors (ACE) inhibitors on the expectation that this bradykinins) but a also variety of vasopressor peptides combination would highlight the effects of natriuretic including angiotensin II and endothelin. In fact, subsequent peptides in the presence of reductions in angiotensin II. studies demonstrated that administration of NEP inhibitors
The benefits of ACE inhibitors in antagonising the was associated with enhancement of vasopressor peptides deleterious effects of angiotensin II (Table 2 ) are now well and of angiotensin II in particular [72, 75, 76] . These established for both hypertension and for congestive heart observations suggested that NEP inhibitors might be more failure. Therefore, inhibition of ACE activity to reduce effective in hypertensive conditions associated with low angiotensin II and neutral endopeptidase to enhance endogplasma renin as in hypertensives of African origin who are enous natriuretic peptides, theoretically at least, should known to have low plasma renin activity [77] .
provide a powerful combination in the treatment of hyRelated studies have also explored the potential benefit pertension or congestive heart failure by potentiating the of NEP inhibitors in conditions associated with overt effects of raised endogenous natriuretic peptides. That this expansion of the extracellular fluid volume and with markedly raised circulating levels of ANP as in chronic renal failure [78] or congestive heart failure [79-83]. Inhibition of NEP also stimulated renal sodium excretion Table 2 Systemic, renal and other effects of angiotensin II (AT receptor) in patients with chronic renal failure. In patients with mild 1 chronic heart failure, candoxatril given acutely demon- 
S-enantiomer of the racemate acetorphan). In this multi-
Macrophage activation ↑ national study [84] , 279 patients with chronic heart failure might be the case was supported by a series of experiments Significant reductions in blood pressure have also been in animals [85] [86] [87] [88] [89] . A combination of ACE and NEP reported in the stroke-prone SHR [99] . Omapatrilat also inhibitors effectively reduced blood pressure in both the improved survival in cardiomyopathic hamsters [100] and SHR and in rats with volume expanded forms of hypertenin sheep with heart failure there were significant acute and sion and displayed beneficial haemodynamic effects in sustained improvements in cardiac haemodynamics and dogs with experimental heart failure renal function [101] . The potential beneficial effects of dual ACE and NEP These haemodynamic effects of vasopeptidase inhibitors was subsequently demonstrated in humans. In one study, are consistent with those expected after activation of the Stergiou et al. [90] found that in hypertensive patients, natriuretic peptide system on a background of reduced candoxatril when added to lisinopril induced substantial activity of angiotensin II. However, consistently raised reduction in both systolic and diastolic blood pressure plasma levels of ANP have not been found in every (219.164.2 and 27.663.0 for supine blood pressures investigation and while this may be due to pharcompared with placebo). Similar reductions were observed macokinetic issues or a consequence of the effects of for standing blood pressure. A separate study [91] with a concomitant reduction in angiotensin II [102] , there is different NEP inhibitor (sinorphan) also reported a syneradditional evidence suggesting that enhanced natriuretic gistic effect in terms of reduction in blood pressure when peptide activity may be an important factor in the cardiac this NEP inhibitor was combined with the ACE inhibitor haemodynamic actions of NEP inhibitors. For example, in captopril.
dogs with heart failure, the cardiac haemodynamic effects A further development was the realisation in the early of omapatrilat were substantially reduced by the natriuretic 1990s about the possibility of encapsulating both NEP and peptide receptor antagonist (HS-124) [103] . However, to ACE inhibitory properties within the same molecule. Both some extent, the effects of neutral endopeptidase inhibitors enzymes are ectopeptidases and both are zinc dependent.
may also involve bradykinin. Apart from natriuretic pepAlso, both enzymes hydrolyse some peptides such as tides and angiotensin II, neutral endopeptidase also inactienkephalins, bradykinins or substance P at the same amide vates bradykinin (Fig. 3) . Reductions in bradykinin breakbond [30, 60] . Although many compounds are highly down have been demonstrated after administration of NEP selective inhibitors of either NEP or ACE activity some inhibitors [93, 104] . Since bradykinin, of course, is also a mercaptoalkyl inhibitors of these enzyme displayed partial substrate for ACE, inhibition of both ACE and NEP inhibition of both enzyme. Further systematic modification therefore is likely to lead to an even greater enhancement of the NEP inhibitor thiorphan led to the development of of endogenous bradykinin. But while bradykinin is a glycoprilat and alatrioprilat as dual inhibitors of NEP and potent vasodilator and has natriuretic properties, the contri-ACE with inhibitory constants in the nanomolar range.
bution of bradykinin in the cardiovascular and renal When tested in rats these were effective in blocking the actions of NEP inhibitors remains to be resolved. pressor effects of angiotensin II and also increased urinary Several vasopeptidase inhibitors including sampatrilat, sodium and urinary cyclic GMP in the absence of a MDL 100,240 and omapatrilat have now been tested in significant kaliuretic effect [92] . humans. Administration of MDL 100,240 in normal Several vasopeptidase inhibitors have been developed humans [105] was associated with a fall in blood pressure and tested for their renal and cardiovascular effects after oral administration in animal models of hypertension and heart failure [93] [94] [95] [96] [97] . These substances are potent inhibitors of both ACE and NEP in vitro with inhibitory constants in the low nanomolar range and equivalent to those of single ACE inhibitors. In the intact animal administration of vasopeptidase inhibitors leads to increases in circulating ANP (and BNP in some cases), urinary cyclic GMP and urinary sodium excretion without a marked effect on potassium excretion in association with substantial reductions in blood pressure. The effects on blood pressure appear to be independent of plasma renin status. In animal experiments, the effects of the vasopeptidase inhibitor omapatrilat on blood pressure were tested in three experimental models characterised by plasma renin levels: normal (SHR), reduced (DOCA-salt rats) and high (SHR on low sodium diet) [98] . After oral administration of omapatrilat there were substantial and design. In this study, sampatrilat displayed a sustained Broad spectrum of action in hypertension decrease in mean ambulatory blood pressure (27.861.5
Preservation of renal blood flow and GFR and 25.260.9 mmHg diastolic, respectively) which was Reduction in preload and afterload in congestive heart failure greater than that obtained with lisinopril.
Investigations in humans confirmed that omapatrilat is a together with the preservation of renal haemodynamics and potent and long-lasting inhibitor of both NEP and ACE increased sodium and urinary volume, atrial natriuretic and in individuals with essential hypertension, omapatrilat peptide and cyclic GMP excretion.
produced dose-related (10-80 mg / day) substantial reducWallis et al. [106] compared the effect of sampatrilat, tions in average blood pressure. Compared with placebo, it lisonopril and placebo in patients with hypertension in a produced greater reductions in systolic blood pressure than randomised double-blind design for 10 days. Whereas there diastolic blood pressure -at 80 mg / daily decreases of was a reduction in blood pressure after the first dose of systolic blood pressure of 20-26 mmHg and of diastolic lisinopril, there was no significant fall in blood pressure 14 and 17 mmHg were reported supporting a once-daily after the initial dose of sampatrilat. However, after 10 days dosing [108, 109] . Comparable reductions in blood pressure of treatment, sampatrilat lowered systolic clinic and amafter omapatrilat have also been found in African-Ameribulatory blood pressure to a similar extent to lisonopril but can as in Caucasians [110] . This is well in agreement with there was a limited effect on diastolic blood pressure.
animal studies suggesting that the antihypertensive effects Sampatrilat increased urinary cyclic GMP suggesting an are not dependent on renin status given the low plasma enhancement of natriuretic peptide activity; however, its renin activity of people of African origin. effect on plasma ACE was much less than that observed Omapatrilat has also been evaluated in patients with with lisonopril and this may possibly account for the congestive heart failure [111-113]. Beneficial haemody- [113] . Concerns about development of angio-oedema [115] 
